Skip to main content

Table 1 Subject demographic & disease characteristics

From: Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study

 

Healthy controls N = 50

Full SLE/MCTD Cohort N = 50

Utilization SLE/MCTD Cohort N = 42

Age in years, median (IQR)

13.4 (11.4,15.2)

16.5 (13.0,17.9)

16.9 (13.0,18.0)

Female, N (%)

30 (60)

43 (86)

38 (90)

Race/Ethnicity, N (%)

   

  Black

26 (52)

18 (36)

15 (36)

  White

13 (26)

23 (46)

21 (50)

  Other

11 (22)

9 (18)

6 (14)

Highest Household Education, N (%)

   

  Less than college

12 (24)

9 (18)

8 (19)

  College and above

38 (76)

41 (82)

34 (81)

Annual Household Income

   

  <$40000

12 (24)

10 (20)

7 (17)

  $40000 and above

34 (68)

30 (60)

25 (60)

  Prefer not answer

4 (8)

10 (20)

10 (24)

Insurance (N,%)

-

  

  Medicaid

 

20 (40)

17 (40)

  Private

 

30 (60)

25 (60)

PRQL, median (IQR)

2.5 (1,5)

1 (0, 4)

1 (0,4)

Diagnosis, N (%)

-

  

  SLE

 

43 (86)

37 (88)

  MCTD

 

7 (14)

5 (12)

Disease Duration in months, median (IQR)

-

23 (11,50)

35 (16, 57)

Disease Manifestations, N (%)

-

  

  Cytopenia

 

42 (84)

37 (88)

  Arthritis

 

37 (74)

30 (71)

  Rash

 

21 (42)

21 (50)

  Nephritis

 

6 (12)

4 (10)

  Serositis

 

6 (12)

6 (14)

  CNS disease

 

3 (6)

3 (7)

  APS (lab only)

 

7 (14)

7 (17)

  APS (lab and clinical)

 

3 (6)

3 (7)

Medications/Treatments, N (%)

-

  

  Hydroxychloroquine

 

49 (98)

41 (98)

  Methotrexate

 

11 (22)

9 (21)

  Mycophenolate Mofetil

 

25 (50)

20 (48)

  Azathioprine

 

2 (4)

2 (5)

  Glucocorticoids*

   

    None

 

16 (32)

15 (36)

    Low-dose

 

28 (56)

25 (59)

    High-dose

 

6 (12)

2 (5)

  Aspirin

 

19 (38)

17 (40)

  History of rituximab

 

7 (14)

7 (17)

  History of cyclophosphamide

 

8 (16)

7 (17)

  History of dialysis

 

1 (2)

0 (0)

Baseline SLEDAI**, median (IQR)

-

2 (0, 4)

2 (0, 4)

SLEDAI in past year**, median (IQR)

-

2 (0, 4)

2 (0, 4)

Baseline PGA**, median (IQR)

-

0 (0, 1)

0 (0,1)

PGA in past year, median (IQR)

-

0.5 (0, 1.5)

0.5 (0,1)

Pain Score**, median (IQR)

-

0 (0, 0)

0 (0,0)

CHAQ Score**, median (IQR)

-

0 (0, 0)

0 (0,0)

  1. Demographic and disease characteristics are presented for the healthy control and SLE/MCTD cohorts. *Low-dose glucocorticoid is <10 mg and high-dose is > =10 mg daily Prednisone equivalent. **Missing data is as follows: PRQL in 11 subjects; baseline SLEDAI in 4 SLE subjects and median SLEDAI in past year in 1 SLE subjects due to unavailability of laboratory data; baseline PGA in 1 subject; CHAQ in 10 subjects; pain score in 6 subjects.